618
Views
22
CrossRef citations to date
0
Altmetric
Reviews

Emerging VEGF-receptor inhibitors for colorectal cancer

, MD PhD, , MD PhD, , MD PhD, , MD PhD, , MD PhD, & show all
Pages 25-37 | Published online: 06 Dec 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

M. Tampellini, C. Sonetto & G. V. Scagliotti. (2016) Novel anti-angiogenic therapeutic strategies in colorectal cancer. Expert Opinion on Investigational Drugs 25:5, pages 507-520.
Read now

Articles from other publishers (21)

Qian Zhong, Xina Xiao, Yijie Qiu, Zhiqiang Xu, Chunyu Chen, Baochen Chong, Xinjun Zhao, Shan Hai, Shuangqing Li, Zhenmei An & Lunzhi Dai. (2023) Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm 4:3.
Crossref
Tian Li & Shi Hu. 2023. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies 137 144 .
Se-Hee Kim, Sangtae Choi & Won-Suk Lee. (2021) Bevacizumab and anexelekto inhibitor, TP-0903 inhibits TGF-β1-induced epithelial–mesenchymal transition of colon cancer cells. Anti-Cancer Drugs 33:1, pages e453-e461.
Crossref
Yu-Chen S. H. Yang, Po-Jui Ko, Yi-Shin Pan, Hung-Yun Lin, Jacqueline Whang-Peng, Paul J. Davis & Kuan Wang. (2021) Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers. Journal of Biomedical Science 28:1.
Crossref
Li-Gang Yu, Su-Qin Chen & Guo-Liang Mao. (2020) Relationship between EZH2 and VEGF expression and prognosis in colorectal cancer. World Chinese Journal of Digestology 28:5, pages 155-166.
Crossref
Xiu-Ping Tong, Xin-Ming Lei & Liu He. (2020) Meta-analysis of safety and efficacy of antiangiogenic drug aflibercept for metastatic colorectal cancer. World Chinese Journal of Digestology 28:1, pages 18-25.
Crossref
Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini, Davide Ciardiello, Valentina Belli, Nunzia Matrone, Giusi Barra, Stefania Napolitano, Carmina Della Corte, Mimmo Turano, Maria Furia, Teresa Troiani, Floriana Morgillo, Ferdinando De Vita, Fortunato Ciardiello & Erika Martinelli. (2019) Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Martini Giulia, Troiani Teresa, Cardone Claudia, Vitiello Pietro Paolo, Ciardiello Davide, Morgillo Floriana, Ciardiello Fortunato & Martinelli Erika. (2019) Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims. Current Cancer Therapy Reviews 15:3, pages 184-191.
Crossref
Hikaru Nagano, Chisato Tomida, Naoko Yamagishi & Shigetada Teshima-Kondo. (2019) VEGFR-1 Regulates EGF-R to Promote Proliferation in Colon Cancer Cells. International Journal of Molecular Sciences 20:22, pages 5608.
Crossref
Giulia Martini, Claudia Cardone, Pietro Paolo Vitiello, Valentina Belli, Stefania Napolitano, Teresa Troiani, Davide Ciardiello, Carminia Maria Della Corte, Floriana Morgillo, Nunzia Matrone, Vincenzo Sforza, Gianpaolo Papaccio, Vincenzo Desiderio, Mariel C. Paul, Veronica Moreno-Viedma, Nicola Normanno, Anna Maria Rachiglio, Virginia Tirino, Evaristo Maiello, Tiziana Pia Latiano, Daniele Rizzi, Giuseppe Signoriello, Maria Sibilia, Fortunato Ciardiello & Erika Martinelli. (2019) EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. Molecular Cancer Therapeutics 18:4, pages 845-855.
Crossref
Yun Dai, George Wilson & Liang Qiao. 2017. Encyclopedia of Cancer. Encyclopedia of Cancer 1128 1135 .
Guido Giordano, Antonio Febbraro, Eugenio Tomaselli, Maria Lucia Sarnicola, Pietro Parcesepe, Domenico Parente, Nicola Forte, Alessio Fabozzi, Andrea Remo, Andrea Bonetti, Erminia Manfrin, Somayehsadat Ghasemi, Michele Ceccarelli, Luigi Cerulo, Flavia Bazzoni & Massimo Pancione. (2015) Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. Journal of Experimental & Clinical Cancer Research 34:1.
Crossref
Xuan Liu, Qing Ji, Zhongze Fan & Qi Li. (2015) Cellular signaling pathways implicated in metastasis of colorectal cancer and the associated targeted agents. Future Oncology 11:21, pages 2911-2922.
Crossref
Lei Wang, Shan Ji & Zeneng Cheng. (2015) Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis. PLOS ONE 10:5, pages e0126619.
Crossref
Ni Liu, Jianyong Yang, Yonghui Huang, Bin Chen, Wei Chen & Jiaping Li. (2015) Vascular Endothelial Growth Factor Accelerates Establishment of a Model of Hepatic Metastasis in Walker-256 Tumor-Bearing Rats. The American Journal of the Medical Sciences 349:3, pages 234-239.
Crossref
Chisato Tomida, Kana Aibara, Naoko Yamagishi, Chiaki Yano, Hikaru Nagano, Tomoki Abe, Ayako Ohno, Katsuya Hirasaka, Takeshi Nikawa & Shigetada Teshima-Kondo. (2015) The malignant progression effects of regorafenib in human colon cancer cells. The Journal of Medical Investigation 62:3.4, pages 195-198.
Crossref
Jonas Kügler. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 1855 1870 .
Teresa Troiani, Stefania Napolitano, Donata Vitagliano, Floriana Morgillo, Anna Capasso, Vincenzo Sforza, Anna Nappi, Davide Ciardiello, Fortunato Ciardiello & Erika Martinelli. (2014) Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. Clinical Cancer Research 20:14, pages 3775-3786.
Crossref
Yun Dai, George Wilson & Liang Qiao. 2014. Encyclopedia of Cancer. Encyclopedia of Cancer 1 8 .
Elena Tsvetkova & Timothy R. Asmis. (2013) How Do We Make Choices in Salvage Therapy: Panitumumab, Cetuximab, or Regorafenib?. Current Colorectal Cancer Reports 9:4, pages 326-330.
Crossref
L. Fornaro, S. Lonardi, G. Masi, F. Loupakis, F. Bergamo, L. Salvatore, C. Cremolini, M. Schirripa, C. Vivaldi, G. Aprile, A. Zaniboni, S. Bracarda, G. Fontanini, E. Sensi, C. Lupi, M. Morvillo, V. Zagonel & A. Falcone. (2013) FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Annals of Oncology 24:8, pages 2062-2067.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.